spec sheet9 rows
4-Methylpregabalin is an investigational gabapentinoid (an alpha2delta calcium-channel ligand) and a close structural analog of pregabalin, carrying an additional methyl group at the 4-position of the aminomethyl-hexanoic-acid backbone (IUPAC 3-(aminomethyl)-4,5-dimethylhexanoic acid). Synthesized by Parke-Davis/Pfizer during structure-activity studies on the gabapentin and pregabalin scaffold, its active (3S,4S) stereoisomer binds the alpha2delta-1 auxiliary subunit of voltage-gated calcium channels with high affinity and produces anticonvulsant, analgesic and anxiolytic activity in preclinical models, in several of which it is reported to be more potent than pregabalin. It was never advanced to clinical trials or market and remains a research compound.
- Binds the alpha2delta calcium-channel subunit more tightly than pregabalin
- Potent anticonvulsant activity across preclinical seizure models
- Reduces neuropathic-pain behaviors such as allodynia and hyperalgesia in animals
- Anxiolytic-like effects in rodent conflict and elevated-maze models
- Curbs excitatory neurotransmitter release without acting on GABA receptors
- Dizziness and somnolence expected as a gabapentinoid class effect
- Sedation and additive CNS depression with alcohol or opioids
- Peripheral edema and possible weight gain by class analogy
- Class-level potential for misuse and a withdrawal syndrome on stopping
Overview
This one is basically pregabalin with a tuning tweak; you add a methyl at the 4-spot and the (3S,4S) isomer grips the alpha2delta subunit even tighter than pregabalin does. On paper that is exactly what you want from a gabapentinoid; more binding, more damping on the calcium side, which is pretty much where the anti-pain and anti-anxiety magic lives. It is a genuinely interesting molecule because it shows how small the structural changes are that separate one alpha2delta ligand from the next. Honest caveat though; this stayed a lab compound and never went through human trials, so treat it as a research chemical and not a stand-in for the approved gabapentinoids.
Mechanism
Like gabapentin and pregabalin, 4-methylpregabalin is a 3-substituted analog that, despite its structure, does not bind or activate GABA-A or GABA-B receptors and does not alter GABA uptake or metabolism. Its real target is the alpha2delta-1 (and to a lesser degree alpha2delta-2) auxiliary subunit of voltage-gated calcium channels.
By binding alpha2delta at presynaptic terminals it reduces depolarization-evoked calcium influx and lowers trafficking of channels to the membrane, which dampens the release of excitatory neurotransmitters such as , noradrenaline and substance P from hyperexcited neurons. Adding the 4-methyl group increases affinity for the alpha2delta site relative to pregabalin, translating into greater potency in animal models of pain and seizure. Like other gabapentinoids it is a substrate of the system L amino acid transporter (LAT1), which carries it across the gut wall and the .
receptor fingerprint
alpha2delta-1 subunit (CACNA2D1) of voltage-gated calcium channelsBinds / inhibits
alpha2delta-2 subunit (CACNA2D2)Binds
Presynaptic voltage-gated Ca2+ channels (P/Q- and N-type)Modulates (indirect)
System L amino acid transporter (LAT1)Substrate
-A / GABA-B receptorsNo functional activity
Safetyrisks and cautions, not medical advice
4-Methylpregabalin is an investigational compound that never completed clinical development, so its human safety profile is not established. By class analogy with pregabalin and gabapentin, expected effects include dizziness, somnolence, sedation, peripheral edema and possible weight gain, with additive CNS depression when combined with alcohol or other sedatives. Gabapentinoids also carry a recognized potential for misuse and a discontinuation/withdrawal syndrome. It is not an approved medicine and should be regarded as a research chemical rather than a substitute for approved gabapentinoids.
Subjective profileweighing the evidence above
A more-potent pregabalin analog that never left the lab; scientifically interesting as a lesson in alpha2delta structure-activity, but investigational and not a substitute for approved gabapentinoids.
Resources
This entry is here for reference.
Research
- 1998first citedIdentification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a…
- 2006most recentPregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons
- 1.3-substituted GABA analogs with central nervous system activity: a review
- 2.Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents
- 3.Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin
- 4.Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity
- 5.Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is 4-methylpregabalin used for?
Nothing approved; it is an investigational gabapentinoid studied in animals for pain, seizures and anxiety, and it never reached human trials or the market.
How does 4-methylpregabalin work?
It binds the alpha2delta-1 subunit of voltage-gated calcium channels, reducing calcium influx and the release of excitatory neurotransmitters; it does not act on GABA receptors despite being a GABA analog.
Is it stronger than pregabalin?
In binding assays and several animal models the active (3S,4S) isomer is reported to be more potent than pregabalin thanks to the added 4-methyl group; that potency has never been confirmed in people.
Is 4-methylpregabalin well-researched?
Only preclinically; it appears in Parke-Davis/Pfizer structure-activity work but has no clinical trials, so its human profile is unknown.
What are the main side effects?
By class analogy the likely effects are dizziness, drowsiness, sedation and edema; because it is unapproved, treat it as a research chemical with an unestablished safety profile.
Adverse effects
- Dizziness and somnolence expected as a gabapentinoid class effect
- Sedation and additive CNS depression with alcohol or opioids
- Peripheral edema and possible weight gain by class analogy
- Class-level potential for misuse and a withdrawal syndrome on stopping
Notes and cautions
- Human safety never established; purely investigational